Proposed Changes to Biosimilar Drug Review Process

Where This Stands

Introduced

Committee

Floor Vote

Passed

Signed

Currently in_committee. The next step in the legislative lifecycle is Floor Vote.

Last action

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.Jul 21, 2026

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

The bill aims to reduce the time and regulatory burden for bringing medications to market, which could impact the availability and pricing of specialized treatments for patients relying on biological therapies.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Pharmaceutical manufacturers

Companies developing biosimilar products will be subject to the updated review procedures established by this amendment.

Patients using biological therapies

Patients may experience changes in the availability or cost of biological treatments depending on how the streamlined review process affects market entry for biosimilars.

What changed

Current stage: in_committee.

What's next

Floor Vote.

Summary

This bill proposes changes to the to simplify and speed up the federal review process for biological products. These are lower-cost versions of complex, high-cost biological drugs.

Why It Matters

The bill aims to reduce the time and regulatory burden for bringing medications to market, which could impact the availability and pricing of specialized treatments for patients relying on biological therapies.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

What is a biosimilar biological product?

A is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.

What is the current status of this bill?

The bill has been read twice and is currently under review by the Senate Committee on Health, Education, Labor, and Pensions.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Focus on Regulatory Efficiency

The bill signals a legislative intent to prioritize the reduction of regulatory hurdles for biosimilar market entry.

Public Health Service Act

Connected Entities

organizationCommittee on Health, Education, Labor, and Pensions“The Senate committee currently reviewing the bill.”Map →

otherPublic Health Service Act“The federal law governing public health and medical product regulation that this”Map →

Analysis Score

0–100

Significance65
How much this matters to a regular citizen
Controversy40
Intensity of disagreement among stakeholders
Entertainment5
Compellingness for a non-policy-wonk reader
Buzz20
Current news / social attention level